Sacituzumab Govitecan-hziy
Sacituzumab govitecan-hziy is a type of drug called an antibody-drug conjugate. Antibody-drug conjugates consist of a monoclonal antibody chemically linked to a cancer-killing drug. Sacituzumab govitecan-hziy is made of a monoclonal antibody linked to a drug called SN-38 that binds to a protein on the surface of some cancer cells. The linked drug enters these cancer cells and kills them. Sacituzumab govitecan-hziy may also stimulate the immune system to kill cancer cells. It is a type of targeted therapy.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Sacituzumab govitecan-hziy is approved to treat adults with:
- Breast cancer that is metastatic (has spread to other parts of the body) or cannot be removed by surgery. It is used:
- In patients with triple-negative cancer who have received at least two systemic therapies, including at least one for metastatic cancer.
- In patients with hormone receptor–positive and HER2–negative cancer who have received hormone therapy and at least two systemic therapies for metastatic cancer.
- Urothelial cancer (a type of cancer in the bladder or urinary tract) that has spread or cannot be removed by surgery. It is used in adults who have received platinum chemotherapy and immunotherapy.¹
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that sacituzumab govitecan-hziy provides a clinical benefit in these patients.
Sacituzumab govitecan-hziy is also being studied in the treatment of other types of cancer.
More About Sacituzumab Govitecan-hziy
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Sacituzumab Govitecan-hziy - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Sacituzumab Govitecan-hziy - Check for trials from NCI's list of cancer clinical trials now accepting patients.